Dr. Knolle is a co-founder of Pharvaris and has served as Chief Scientific Officer and Chief Operating Officer since its inception. Jochen’s experience spans 30 years in the pharmaceutical industry, and encompasses every aspect of drug discovery, development and registration. Jochen is named as author of many publications and as an inventor for many patents, including the approved therapeutics quinapril and icatibant.
From 1978 to 1998, Jochen worked in several functions in the central pharmaceutical research unit of Hoechst AG and Hoechst-Marion-Roussel (HMR). In 1998, Jochen left HMR to join Axys Pharmaceuticals (now Celera) in San Francisco, where he served as VP for Medicinal Chemistry and structural biology. From 2001-2008, Jochen was the Chief Scientific Officer and Head of R&D in the management board of Jerini AG in Berlin, Germany. In 2001, Jochen in-licensed icatibant, a former research project of his, from Aventis. In 2008, icatibant was approved in the EU and is marketed now in more than 40 countries including the US under the trade name Firazyr. While at Jerini, Jochen was instrumental for the collaborations with Merck, Kos Pharmaceuticals and Abbott, academic collaborations, private financing rounds and the IPO of Jerini at the German Stock Exchange Frankfurt in 2005. In 2008, Shire acquired Jerini. After completion of the transaction, Jochen resigned from the management board of Jerini in October 2008 and established JCK Consult.
In addition to his consultancy activities, Jochen was a co-founder of Kosa Pharma and 3BPharmaceuticals and acts as a board member for the Charité CRO, and Thermosome, as a Scientific Advisory Board member for OMEICOS Therapeutics, and as Senior Advisor for Kurma Partners. Jochen studied chemistry in Göttingen and Münster. After a post-doc in the laboratory of the Nobel Laureate E.J. Corey at Harvard University, Jochen joined the pharmaceutical unit of Hoechst AG in 1978.